<DOC>
	<DOCNO>NCT02957968</DOCNO>
	<brief_summary>This study 2-cohort , open-label , multicenter , phase 2 study short course immunotherapy consist sequential decitabine follow pembrolizumab administer prior standard neoadjuvant chemotherapy regimen patient locally advance HER2-negative breast cancer . The primary efficacy objective determine immunotherapy increase presence percentage tumor and/or stromal area infiltrate lymphocyte prior initiation standard neoadjuvant chemotherapy . Efficacy evaluate 2 cohort base hormone receptor status .</brief_summary>
	<brief_title>Neoadj Pembrolizumab + Decitabine Followed Std Neoadj Chemo Locally Advanced HER2- Breast Ca</brief_title>
	<detailed_description>Both cohort receive identical dos treatment schedule decitabine pembrolizumab follow standard neoadjuvant chemotherapy regimen . Both cohort receive 4 cycle dose-dense AC follow 12 dos weekly paclitaxel . Paclitaxel combine carboplatin Cohort A ( TNBC ) . The primary safety objective evaluate safety toxicity sequential decitabine plus pembrolizumab follow dose-dense AC , weekly paclitaxel ( paclitaxel plus carboplatin ) administer neoadjuvant therapy . If breast tumor resectable follow completion protocol therapy , breast-conserving surgery mastectomy axillary surgical staging ( either sentinel node biopsy and/or axillary dissection ) perform .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Invasive adenocarcinoma breast diagnose core needle biopsy Breast cancer determine HER2negative per current American Society Clinical Oncologists/College American Pathologists ( ASCO/CAP ) HER2 Guidelines ( If IHC perform , IHC 0 1+ ; fluorescence situ hybridization [ FISH ] situ hybridization test , dual probe HER2/CEP17 ratio &lt; 2.0 average HER2 copy number &lt; 4.0 signals/cell ) Breast cancer determine hormone receptorpositive ( ie , ≥ 1 % estrogen receptor [ ER ] and/or progesterone receptor [ PgR ] stain IHC ) hormone receptornegative ( ie , &lt; 1 % ER PgR stain IHC ) Locally advance breast cancer define follow per American Joint Committee Cancer ( AJCC ) Staging Criteria : T2 clinically positive regional lymph node ( cN1 cN2 ) Any T3 Any T4 ( include inflammatory breast cancer ) Ipsilateral axillary lymph node must evaluate MRI within 12 week prior study registration determine clinical nodal status . If image suspicious abnormal , FNA core biopsy questionable node ( ) imaging require . Nodal status classify accord follow criterion : Nodal status negative Imaging axilla negative ; OR Imaging axilla suspicious abnormal AND FNA core biopsy negative . Nodal status positive FNA core biopsy node ( ) cytologically histologically suspicious positive Breast imaging perform prior study registration follow : Ipsilateral breast within 12 week Contralateral breast within 24 week Age ≥ 18 year Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate bone marrow function define : Absolute neutrophil count ( ANC ) ≥ 1,500/mm3 Platelet count ≥ 100,000/mm3 Hemoglobin ≥ 10.0 g/dL Adequate renal function define : Serum creatinine ≤ upper limit normal ( ULN ) lab calculate creatinine clearance ≥ 60 mL/min Adequate hepatic function define : Total bilirubin ≤ ULN laboratory Aspartate aminotransferase ( AST ) ≤ 1.5 x ULN laboratory Alanine aminotransferase ( ALT ) ≤ 1.5 x ULN laboratory Alkaline phosphatase ( ALP ) ≤ 1.5 x ULN laboratory Note : If AST , ALT , and/or ALP &gt; ULN , image rule bone liver metastasis require . LVEF assessment ( ie , 2D echocardiogram MUGA scan ) perform within 12 week prior study registration indicate LVEF ≥ 50 % regardless cardiac image facility 's low limit normal Women postmenopausal undergone hysterectomy must document negative serum pregnancy test within 72 hour prior initiate study treatment . Note : Postmenopausal define follow : Age ≥ 60 year Age &lt; 60 year amenorrheic least 1 year folliclestimulating hormone ( FSH ) plasma estradiol level postmenopausal range Bilateral oophorectomy A female patient woman childbearing potential ( WCBP ) male patient partner WCBP must agree use medically accept method preventing pregnancy duration immunotherapy neoadjuvant chemotherapy completion breast surgery , patient receive neoadjuvant chemotherapy , minimum 4 month follow last dose pembrolizumab Ability understand willingness sign consent form Breast cancer treatment currently diagnose breast cancer include radiation therapy , chemotherapy , target therapy , endocrine therapy prior study registration Administration live vaccine within 30 day prior initiate study treatment Note : Seasonal influenza vaccine injection generally inactivate flu vaccine permit ; however , intranasal influenza vaccine ( eg , FluMist ) live attenuate vaccine , allow . Administration monoclonal antibody within 4 week prior initiate study treatment recover ( ie , ≤ grade 1 baseline ) AEs due agent administer 4 week early Administration investigational agent within 4 week prior initiate study treatment Evidence metastatic disease extensive enough preclude consideration subsequent definitive surgery primary tumor History ipsilateral invasive breast cancer ipsilateral ductal carcinoma situ ( DCIS ) Note : Patients history ipsilateral lobular carcinoma situ ( LCIS ) eligible . Previous therapy malignancy anthracycline taxane Cohorts A B carboplatin Cohort A Cardiac disease would preclude administration drug include study treatment regimen include , limited : Angina pectoris require current use antianginal medication Ventricular arrhythmia except benign premature ventricular contraction Supraventricular nodal arrhythmia require pacemaker control medication Conduction abnormality require pacemaker Valvular disease document compromise cardiac function ; symptomatic pericarditis Nervous system disorder ( ie , paresthesia , peripheral motor neuropathy , peripheral sensory neuropathy ) ≥ grade 2 , per CTCAE v4.0 Administration condition require administration systemic steroid therapy form immunosuppressive therapy within 7 day prior initiate study treatment Exception : Patients condition manage steroid equivalent less oral prednisone dose 10 mg daily would exclude study . Previous therapy cancer antiPD1 , antiPDL1 , antiPDL2 agent , immunomodulatory agent Known presume hypersensitivity decitabine pembrolizumab ( excipients ) Diagnosed immunodeficiency , eg , human immunodeficiency virus ( HIV ) Active autoimmune disease require systemic treatment within past 2 year ( ie , use diseasemodifying agent , corticosteroid , immunosuppressive drug ) document history clinically severe autoimmune disease syndrome require systemic steroid immunosuppressive agent Note : Patients condition medical history list NOT exclude study . Vitiligo Resolved childhood asthma/atopy Requirement intermittent use bronchodilator local steroid injection topical steroid Hypothyroidism stable hormone replacement Sjogren 's Syndrome Known history evidence interstitial lung disease active , noninfectious pneumonitis Known history active bacillus tuberculosis ( TB ) Active infection require systemic therapy Known active Hepatitis B C Pregnancy breastfeed Diagnosis treatment another malignancy within 5 year prior study registration , follow exception : complete resection basal cell carcinoma squamous cell carcinoma skin , situ malignancy , lowrisk prostate cancer curative therapy Medical , psychological , social condition , opinion investigator , may increase patient 's risk limit patient 's adherence study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Invasive adenocarcinoma</keyword>
	<keyword>HER2-negative</keyword>
</DOC>